A phase II clinical trial was investigated the clinical benefit of exosomes that were derived from IFN-γ-matured dendritic cells and loaded with MHC class I- and II-restricted cancer antigens as maintenance immunotherapy after induction chemotherapy in patients with inoperable non-small cell lung cancer without tumor progression. Here, IFNG is linked to neoplasm.